Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Condition: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - Hôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Drug: Autologous Natural Killer Cell Therapy; Device: Clinimacs Plus Sponsor: Dr Cipto Mangunkusumo General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Condition: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - Hôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Drug: Autologous Natural Killer Cell Therapy; Device: Clinimacs Plus Sponsor: Dr Cipto Mangunkusumo General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Condition: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - Hôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Drug: Autologous Natural Killer Cell Therapy; Device: Clinimacs Plus Sponsor: Dr Cipto Mangunkusumo General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Condition: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - Hôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Conditions: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Interventions: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - H ôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
Conditions: Liver Transplant; Complications; Hepatocarcinoma; Recurrent Osteosarcoma; High-Risk Cancer Intervention: Drug: multi-kinase inhibitors in combination with bevacizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials